Efficacy and Safety of Effusion Associated Lymphocytes Combined with IL-2 in Patients with Malignant Pleural Effusion

Kyong-Jin Pak#, Sven-Christian Schmidt#, Jong-Chol Kil, Yong-Soek O, Sung Jun Choe, Chol-Kim and Yong-Jin Ryu

Department of Thoracic Oncology, Academy of Medical Science, Pyongyang, D.P.R. Korea
Department of Upper GI Surgery, Ernst von Bergmann Clinic, Potsdam, Germany
Department of Thoracic Surgery, Kim II Sung University, Pyongyang, D.P.R. Korea
These authors contributed equally

^*Correspondance to: Sven-Christian Schmidt 

 PDF  Full Text DOI: 10.25107/2474-1647.2406

Abstract

Objective: To determine the effects of Effusion Associated Lymphocytes (EALs) Combined with IL-2 in Patients with Malignant Pleural Effusion (MPE). Material/
Methods: A prospective study was conducted at Oncology Institute, Academy of Medical Science. A total of 100 symptomatic MPE cases were randomized to receive EALs combined with IL-2 therapy (study group) vs. pleurodesis with talc slurry (control group).
Results: 51 cases in the study group and 49 cases in the control group completed the study. There was no difference between the two groups in the patient data and clinical characteristics. The overall response at 30 days was 90.2% in the study group, comparable to the control group (91.8%, p=0.65). But there were significant differences between the two groups in the treatment-related adverse reactions. The pain score and percentage of cases who needed morphine (3.9% vs. 30.6%, p<0.001), percentage of fever (9.8% vs. 30.6%, p=0.03), amount of diclofenac natrium required by each participant (2.2 ± 0.7 vs. 4.6 ± 0.9 tablets, p=0.03), and hospital stay (8.2 ± 2.5 vs. 11.8 ± 3.4, p=0.04) were significantly lower in the study group.
Conclusion: The combination of EALs and IL-2 had an equivalent efficacy compared to talc pleurodesis for MPE treatment. The combination of EALs and IL-2 offered few side effects and shorten hospital stays compared to talc pleurodesis for MPE treatment.

Keywords

Effusion Associated Lymphocytes (EALs); IL-2 Malignant Pleural Effusion (MPE); Talc

Cite the article

Pak K-J, Schmidt S-C, Kil J-C, Yong-Soek O, Choe SJ, Chol-Kim, et al. Efficacy and Safety of Effusion Associated Lymphocytes Combined with IL-2 in Patients with Malignant Pleural Effusion. Clin Surg. 2019; 4: 2406.